Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology
NCT ID: NCT04296201
Last Updated: 2021-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2020-09-01
2021-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The procedure will include treatments with the Legend Pro™ DMA™ technology. Photos will be obtained at pre-defined time points throughout the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
NCT01380964
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography
NCT03490214
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
NCT01749943
Lutronic LaseMD for Treatment of Benign Pigmented Lesions
NCT03409952
A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)
NCT00018109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study population will be divided into three arms as follows:
* 5 female subjects will receive treatment in the face area
* 5 female subjects will receive treatment in the buttocks area
* 5 male subjects will receive treatment in the abdominal region
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment in the face area
5 female subjects will receive treatment in the face area
DMA treatment
Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
Treatment in the buttocks area
5 female subjects will receive treatment in the buttocks area
DMA treatment
Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
Treatment in the abdominal region
5 male subjects will receive treatment in the abdominal region
DMA treatment
Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DMA treatment
Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy male or female aged 25-45 years,
3. Fitzpatrick skin type 1-6
4. Subject is capable of reading, understanding and following instructions of the procedure to be applied.
5. Subject is able and willing to comply with the treatment.
6. Women of child-bearing potential are required to use two forms of reliable methods of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or abstinence) during the course of the study.
Exclusion Criteria
1. Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
2. Concurrent participation in any other study.
Specific to the treatment and treatment area
3. Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
4. Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
5. Subject has significant concurrent skin conditions affecting areas to be treated such as sores, bleeding, skin fragility, eczema or psoriasis.
6. Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
Other treatments
7. Subject has used oral isotretinoin (Accutane or Roaccutan®) within 6 months prior to study enrollment or plans use during the course of the study.
8. Subject has used topical retinoids in past 1 month
Medical conditions/ use of medication
9. Subject has current or history of systemic cancer; premalignant skin lesion or skin concern treatment area.
10. Subject has severe concurrent conditions such as epilepsy, autoimmune, pulmonary or cardiac disorders.
11. Subject has poorly controlled endocrine disorders such as diabetes.
12. Subject has an impaired immune system due to immunosuppressive diseases such as HIV or AIDS, or use of immunosuppressive medications.
13. Subject has history of collagen disorders, keloid formation or abnormal wound healing.
14. Subject takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing
15. Subject has used oral steroids in past 6 months
16. Subject has used topical steroids in past 3 months
17. Subject has history of bleeding coagulopathies or use of anticoagulants.
18. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment
19. Subject has mental disorders that in the opinion of the Investigator would be interfere with ability to comply with the study requirements.
20. Subject has any other medical condition that in the opinion of the Investigator warrants exclusion from this study
25 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lumenis Be Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology, Laser, and Vein Specialists of the Carolinas, PLLC
Charlotte, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUM-ABU-DMA-20-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.